tbuckley/cabot-search huggingface dataset:
Abstract 17786: Epinephrine Administration (EA) During Cardiopulmonary Resuscitation (CPR) Increases Cerebral Tissue Oxygen Saturation: Study With Pulse-observing Mode of Near-infrared Spectroscopy
Authors: Hitoshi Kano, Tomoyo Saito, Keisuke Bando, Toshihisa Matsui, Akio Endo, Keisuke Sakurai, Norifumi Katsumi, Masaki Nagama, Hisako Sageshima, Shuhei Takauji, Yoshinori Homma, Yutaka Dannoura, Hiroshi Komatsu, Yutaka Matsui, Takao Makino, Hiroshi Makise
Journal: Circulation (2015)

Introduction: Recently, the effectiveness of the EA during CPR has been questioned. For some time, we have been analyzing the cerebral tissue oxygen saturation observed during CPR. During AHA 2014, we reported the possibility that an increase in the cerebral tissue oxygenation index (TOI) would predict the recovery of spontaneous circulation (ROSC). This time, we report the results of our clinical study about the relationship between the EA and changes in TOI. Methods: In 59 patients undergoing out-of-hospital cardiac arrest, the blood pulsation waveform and TOI in the brain were continuously monitored with the NIRO-200NX system (Hamamatsu Photonics K.K., Japan) using its pulse-observing mode (NIRO-Pulse mode). The total number of EAs was 86 and, as shown in the figure, the initial and terminal TOIs in the CPR before EA (2 minutes) and the initial and terminal TOIs in the CPR after EA (2 minutes) were measured. Results: The initial and terminal TOIs before EA were 37.6±7.2% and 40.0±7.2% respectively, and the increase in TOI during the CPR (αTOI) was 2.4±3.4%. On the other hand, the initial and terminal TOIs after EA were 37.6±6.6% and 44.0±8.4% respectively, and the αTOI was 6.5±4.8%. Discussion: Since the observation of blood pulsation is not possible with conventional cerebral oxygenation monitors, the relationship between the administration of CPR and changes in cerebral tissue oxygen saturation has not been made clear. However with the NIRO-Pulse mode, the changes in TOI caused by CPR are clearly observed. And, our observation that the terminal TOI and αTOI in the CPR after EA were significantly higher than those before EA suggests that cerebral tissue oxygen saturation is improved by EA. On the other hand, the increase in TOI caused by EA (αTOI) has a certain variation, which suggests the most effective time to administer epinephrine would exist and its effects would differ depending on each patient.
Exploratory analysis of the effect of FTD/TPI in patients treated in RECOURSE by prognostic factors.
Authors: Josep Tabernero, Alberto F. Sobrero, Christophe Borg, Atsushi Ohtsu, Robert J. Mayer, Loïck Vidot, Shanti Ricardo Moreno Vera, Eric Van Cutsem
Journal: Journal of Clinical Oncology (2019)

677 Background: The Phase III RECOURSE trial, in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies, demonstrated that trifluridine/tipiracil (FTD/TPI) significantly extended overall survival (OS) and progression-free survival (PFS) versus placebo in all subgroups, regardless of age, geographical origin, or KRAS status, with acceptable safety. Literature reports have shown optimal benefit for pts with low tumor burden (&lt; 3 metastatic sites), indolent disease (≥ 18 mo since diagnosis of first metastasis), ECOG PS 0-1, and no liver metastasis when treated in late line mCRC. Methods: This exploratory post hoc analysis of RECOURSE (all ECOG 0-1) compared pts on FTD/TPI or placebo with good prognostic characteristics (GPC; low tumor burden and indolent disease) and poor prognostic characteristics (PPC; high tumor burden and/or aggressive disease). These subgroups were then analyzed by liver metastasis at baseline, ECOG PS, KRAS status and age. Results: Baseline characteristics were generally similar between the two groups. GPC placebo pts performed better than the PPC placebo pts, but worse than the GPC pts treated with FTD/TPI. GPC pts treated with FTD/TPI showed median OS of 9.3 mo versus 5.3 mo in PPC pts (HR 0.46; 95% CI: 0.37, 0.57; p &lt; 0.0001); there was a similar effect for PFS. GPC pts had significantly better mOS and mPFS regardless of age (≥ 65 vs. &lt; 65 y), ECOG PS (0–1), KRAS status (mutant vs. wildtype), and liver metastasis (y/n). No liver metastasis was the best prognostic factor: mOS in such pts treated with FTD/TPI was 16.4 mo and 7.6 mo in the GPC (n = 97) and PPC (n = 35) groups, respectively (HR 0.42; 95% CI: 0.24, 0.74; p &lt; 0.0019); there was a similar effect for PFS. Pts with ECOG PS 0 at baseline remained PS 0-1 at discontinuation in 96% of the GPC group. Conclusions: Low tumor burden and indolent disease indicate good prognosis in late line mCRC. Pts with no liver metastasis have the best prognosis and are likely to have longer OS. GPCs might explain the percentage of long-term responders on FTD/TPI in RECOURSE. Maintenance of ECOG PS 0–1 during treatment is crucial in the continuum of care, allowing pts to benefit from further treatment options. Clinical trial information: NCT01607957.
The MRD-Negativity Rate Measured By Flow Cytometry after the 1st and the 2nd Induction Course Among CR AML Patients from Different Cytogenetic Subgroups Does Not Differ Though the Morphological CR Achievement Does
Authors: Elena Parovichnikova, Vera V. Troitskaya, Irina V. Galtseva, Tatiana I. Lobanova, Yuliya O. Davydova, Nikolay M. Kapranov, Andrey N. Sokolov, Alina V. Kokhno, Roman V. Tivikov, Irina A. Lukyanova, Tatiana N. Obukhova, Valery G. Savchenko
Journal: Blood (2018)
Concurrent cerebral aspergillosis and abdominal mucormycosis during ibrutinib therapy for chronic lymphocytic leukaemia
Authors: A. Pouvaret, R. Guery, M. Montillet, T.J. Molina, A. Duréault, M.E. Bougnoux, R. Galliot, F. Lanternier, R. Delarue, O. Lortholary
Journal: Clinical Microbiology and Infection (2019)
Plasma GH as a diagnostic and prognostic biomarker in HCC without cirrhosis.
Authors: Roberto Carmagnani Pestana, Manal Hassan, Reham Abdel-Wahab, Yehia I. Abugabal, Lauren Girard, Rikita Hatia, Van Nguyen, Kanwal Pratap Singh Raghav, Jeffrey Morris, Asif Rashid, Robert A. Wolff, Hesham M. Amin, Ahmed Omar Kaseb
Journal: Journal of Clinical Oncology (2019)

227 Background: The association between the GH/IGF-1 axis and HCC was reported in patients (pt) with underlying cirrhosis. However, there is limited information among HCC pt without (w/o) cirrhosis. We herein investigated the role of GH as a circulating biomarker for HCC diagnosis and prognosis in pt w/o cirrhosis. Methods: Under IRB approval, we prospectively enrolled 1267 newly-diagnosed HCC pt in a case control study at the MD Anderson Cancer Center (2000-2015). Controls were healthy individuals (n = 1104). Plasma GH and AFP were measured 274 HCC pt w/o cirrhosis 200 healthy controls. IGF-1 was measured in 133 and 82 pt, respectively. We classified HCC pt into higher and lower GH values (cutoff for women, 3.7 µg/L; men, &gt; 0.9 µg/L). Results: Most pt (74%) were male, with advanced BCLC staging (C-D, 74%) and 61% were older than 60y. Baseline GH was higher in HCC w/o cirrhosis (mean 3.3 µg/L) than controls (mean 0.4 µg/) (p &lt; .001). ROC curve was plotted to assess diagnostic role. The AUC for AFP was 82.9 (p &lt; .001); for GH 78.2 (p &lt; .001). When only non-cirrhotic HCC pt with early stage (CLIP 0-2) and AFP &lt; 20 ng/m were compared to controls, the GH/IGF-1 ratio had high prediction of early stage HCC - AUC 83 (95% CI 78-89%) (p &lt; .0001). At a specificity of 90%, sensitivity of GH/IGF ratio was 67%. In addition, among HCC w/o cirrhosis, higher GH levels correlated with presence of vascular invasion (p &lt; .001) and thrombosis (p = .004), tumor involvement of &gt; 50% liver (p = .003), and more advanced BCLC (p &lt; .001) and TNM staging (p &lt; .001). Median overall survival (months) of HCC pt w/o cirrhosis with high GH levels was 13.1 (10.8-15.4) compared to 37.4 (19.8-55.1) of pt with lower plasma GH (p &lt; .001). Multivariate cox-regression analysis identified high GH as an independent risk factor for mortality (HR = 1.8; 95% CI, 1.3-2.4; p &lt; .001). Conclusions: Our study demonstrates the diagnostic and prognostic role of plasma GH in non-cirrhotic HCC and identifies the GH/IGF-1 ratio as a promising diagnostic marker for early stage HCC w/o cirrhosis and low AFP; this analysis excludes the confounding effect hepatocyte impaired function by presence of cirrhosis. Further studies are warranted to assess the causes of the observed differences.
Aurone derivatives as Vps34 inhibitors that modulate autophagy
Authors: Guodong Li, Joshua William Boyle, Chung-Nga Ko, Wu Zeng, Vincent Kam Wai Wong, Jian-Bo Wan, Philip Wai Hong Chan, Dik-Lung Ma, Chung-Hang Leung
Journal: Acta Pharmaceutica Sinica B (2019)

We report in this study the identification of a natural product-like antagonist (1a) of Vps34 as a potent autophagy modulator via structure-based virtual screening. Aurone derivative 1a strongly inhibited Vps34 activity in cell-free and cell-based assays. Significantly, 1a prevents autophagy in human cells induced either by starvation or by an mTOR inhibitor. In silico modeling and kinetic data revealed that 1a could function as an ATP-competitive inhibitor of Vps34. Moreover, it suppressed autophagy in vivo and without inducing heart or liver damage in mice. 1a could be utilized as a new motif for more selective and efficacious antagonists of Vps34 for the potential treatment of autophagy-related human diseases.
Correlation of UHRF1 expression in primary prostate cancer patients with adverse prognosis.
Authors: Enrico Roggero, Manuela Sarti, Sandra Pinton, George Thalmann, Carlo Catapano, Ian Marc Bonapace, Giuseppina Carbone
Journal: Journal of Clinical Oncology (2012)

4661 Background: Cancer of the prostate is a leading cause of cancer death in western countries. There is a great need to understand the clinical course of the disease and to distinguish the indolent tumors from those with aggressive behavior. Epigenetic mechanisms play an essential role in cancer initiation and progression. Our groups have recently provided evidence that over-expression of UHFR1 (ubiquitin-like with PHD and ring finger domain) leads to prostate cancer progression by activating a robust epigenetic switch involving silencing of a network of tumor suppressor genes. The purpose of this study was to evaluate in a clinical setting the prognostic impact of UHFR1 expression. Methods: In a series of 225 eligible patients (median age 63 years, range 44-75) with prostate cancer treated in a single institution with prostatectomy between 1990 and 1999 we evaluated the tumor nuclear expression of UHRF1 by immunohistochemistry (IHC). Clinical and histological data of the series were also reviewed. The UHFR1 expression (evaluated in tissue microarrays by immunohistochemistry) and prognostic factors were analyzed using univariate analyses and multivariate logistic regression analysis to identify association with overall survival (OS). Results: The median FU for the series was 137 months (range 1-229), eighty-one patients died (median FU 85 months). In Ninety-seven patients (43%) the UHRF1 expression was positive. In univariate analyses Gleason Score (&lt;7 vs 7-9), Stage Risk Group (TNM Stage &lt;III vs Stage III and/or N+) and UHFR1 expression (negative vs positive) were significant prognostic factors for OS with p-value &lt;0.0001. In multivariate analyses Gleason Score, Stage Risk Group and UHFR1 expression were independent predictors for OS with respectively HRs of 2.77 (95% CI 1.72-4.46) p&lt;0.0001, HRs of 1.96 (95% CI 1.14-3.37) p=0.014 and Hrs 1.35 (95% CI 1.02-1.78) p=0.030. Conclusions: Our results indicate that expression of UHFR1 protein, independently from historical prognostic factors, is linked with adverse prognosis for overall survival in a homogeneous primary prostate cancer treated group with long-term follow-up.
Large-area MRI-compatible epidermal electronic interfaces for prosthetic control and cognitive monitoring
Authors: Limei Tian, Benjamin Zimmerman, Aadeel Akhtar, Ki Jun Yu, Matthew Moore, Jian Wu, Ryan J. Larsen, Jung Woo Lee, Jinghua Li, Yuhao Liu, Brian Metzger, Subing Qu, Xiaogang Guo, Kyle E. Mathewson, Jonathan A. Fan, Jesse Cornman, Michael Fatina, Zhaoqian Xie, Yinji Ma, Jue Zhang, Yihui Zhang, Florin Dolcos, Monica Fabiani, Gabriele Gratton, Timothy Bretl, Levi J. Hargrove, Paul V. Braun, Yonggang Huang, John A. Rogers
Journal: Nature Biomedical Engineering (2019)
O73 PROGNOSTIC VALUE OF MUSCLE ATROPHY IN CIRRHOSIS USING PSOAS MUSCLE THICKNESS ON COMPUTED TOMOGRAPHY
Authors: C. Francoz, O. Roux, C. Laouenan, F. Dondero, S. Dokmak, J. Belghiti, D. Valla, V. Vilgrain, F. Durand
Journal: Journal of Hepatology (2014)
Anti-CD20 Monoclonal Antibodies Hijack the B-Cell Receptor Signaling Cascade Thereby Activating the NOTCH1 Signaling Pathway
Authors: Jennifer Edelmann, David James Britton, Emma Vilventhraraja, Arran Dokal, Karlheinz Holzmann, Mark C Cragg, Andrejs Braun, Pedro Cutillas, John G. Gribben
Journal: Blood (2018)
Phase I study of preoperative capecitabine and lenvatinib with external radiation therapy in locally advanced rectal adenocarcinoma.
Authors: Ankita Tandon, Jessica Frakes, Rutika Mehta, Sarah E. Hoffe, Maria E Martinez Jimenez, Iman Imanirad, Julian Sanchez, Mokenge Peter Malafa, Seth Felder, Sophie Dessureault, Richard D. Kim
Journal: Journal of Clinical Oncology (2020)

125 Background: Neoadjuvant chemo-radiation is a standard of care for locally advanced rectal cancer. Patients with pathologic complete response (pCR) have improved outcomes with less local and systemic failure. Dual targeting with platelet derived growth factor (PDGF) and vascular endothelial growth factor receptor (VEGFR) in combination with radiation can escalate tumor response with radiation. Lenvatinib is an oral multi-kinase inhibitor and had shown potent anti-tumor activity in xenograft models cultured with human colorectal cancer (CRC) lines. Methods: Patients with stage II or III rectal cancer, confirmed by endoscopic ultrasound or MRI, were recruited in 3 cohorts of 3 patients per dose level, with an expansion cohort at the MTD. Lenvatinib oral daily dose started at 14 mg (cohort 1) and was escalated to 20 mg (cohort 2) followed by 24 mg (cohort 3). In this 3+3 design, patients received dose escalation of lenvatinib with standard doses of capecitabine (850 mg/m 2 PO BID) concurrent with external beam radiation on days 1-5 weekly for 28 treatments. Following completion patients underwent surgery in 6-10 weeks. Results: Twenty patients with median age of 55 were enrolled in 3 cohorts (1 patient was ineligible). There were no dose limiting toxicity at the maximum tested dose of lenvatinib (24 mg). Two patients are still awaiting surgery. 12 patients have undergone low anterior resection and 5 patients have had abdominoperineal resection. Therefore, out of 17 patients, 29.4% (5/17) showed pCR, and downstaging was observed in 71% of the patients (12/17). The mean neoadjuvant rectal cancer score (NAR) was 11.4 and median NAR was 8.43. Six patients had grade 3 adverse events (AEs) (1 rectal pain,1 transaminitis, 2 lymphopenia, 1 HTN, 1 with both leukocytosis and hyponatremia). No grade 4 AEs were noted. Most common AEs were hypertension, rectal pain, nausea, diarrhea, fatigue and dermatitis. No peri operative complications were observed. Conclusions: The study shows that the combination of lenvatinib and capecitabine with radiation is well tolerated in locally advanced rectal cancer with promising mean NAR score. The encouraging results will need to be validated in a randomized study. Clinical trial information: NCT02935309.
Type-1 Interferon and Th2-Type Gene Expression Responses and Childhood Asthma
Authors: Jamie A. Rosenthal, Malisa T. Smith, Michelle A. Gill, Andrew H. Liu, Rebecca S. Gruchalla, George T. O'Connor, Jacqueline A. Pongracic, Carolyn Kercsmar, Gurjit K. Khurana Hershey, Edward M. Zoratti, Stephen J. Teach, Meyer Kattan, Leonard B. Bacharier, Avraham Beigelman, Cristina L. Swanson, Scott Presnell, Steve M. Sigelman, Peter J. Gergen, Lisa M. Wheatley, Alkis Togias, William W. Busse, Daniel J. Jackson, Matthew C. Altman
Journal: Journal of Allergy and Clinical Immunology (2019)
Nano‐in‐Micro Smart Hydrogel Composite for a Rapid Sensitive Immunoassay
Authors: Myat Noe Hsu, Shih‐Chung Wei, Dinh‐Tuan Phan, Yong Zhang, Chia‐Hung Chen
Journal: Advanced Healthcare Materials (2019)

Abstract Immunoassays are an important tool in various bioanalytical settings, such as clinical diagnostics, biopharmaceutical analysis, environmental monitoring, and food testing. An enzyme‐linked immunosorbent assay (ELISA) is usually used to amplify immunoassay signals; however, it requires labor‐intensive and time‐consuming procedures, which hinders its application to rapid cytokine detection. In this study, a nano‐in‐micro composite system, where immunosensing polystyrene beads (≈320 nm) are incorporated within a stimuli‐responsive microgel matrix (≈40 µm) via microfluidics, is investigated. The intrinsic volume phase‐transition change properties of the smart microgels allows an enzyme‐free enhanced immunoassay, enabling instant enhancement in signal‐to‐noise ratios of ≈5‐fold. This nano‐in‐micro hydrogel composite offers a simple yet highly effective method for sensitive and multiplexed cytokine analysis without complex enzyme‐based signal amplification steps, greatly benefitting advanced immune medicine.
Impact of Allogeneic Hematopoietic Cell Transplantation (allo-HCT) on the Outcomes of Angioimmunoblastic T-Cell Lymphoma (AITL): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis
Authors: Narendranath Epperla, Kwang Woo Ahn, Carlos Litovich, Mohamed A Kharfan-Dabaja, Sonali M. Smith, Anna Sureda, Timothy S. Fenske, Mehdi Hamadani
Journal: Blood (2018)
Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?
Authors: Cinta Hierro, Ignacio Matos, Juan Martin-Liberal, Maria Ochoa de Olza, Elena Garralda
Journal: Clinical Cancer Research (2019)

Over the last several years, several molecular aberrations have been unevenly described across cancers, although the distinct functional relevance in each biological context is not yet fully understood. Novel discoveries have led to the development of drugs tailored to the molecular profile of patients, thus increasing the likelihood of response among biomarker-selected patients. In this context, there has been a progressive redefinition of a precision medicine framework where evidence-based development and earlier approvals might now be driven by this molecular information. Innovative trial designs have greatly facilitated the evaluation and approval of new drugs in small cohorts of orphan cancers in which histology-dependent molecularly defined trials might be logistically difficult. However, accelerated approvals based on this agnostic-histology development model have brought new clinical, regulatory, and reimbursement challenges. In this article, we will highlight many of the biologic issues and clinical trial design challenges characterizing the development of tissue-agnostic compounds. Also, we will review some of the key factors involved in the development of pembrolizumab and larotrectinib, the first two drugs that have been approved by the U.S. Food and Drug Administration in an histology-agnostic manner. Because we anticipate that agnostic-histology approvals will continue to grow, we aim to provide insight into the current panorama of targeted drugs that are following this strategy and some premises to take into consideration. Clinicians and regulators should be prepared to overcome the associated potential hurdles, ensuring that uncertainties are dealt with properly and allowing new, promising agents to arrive faster to the market.
Immunotherapy for Peanut Allergy Shows Promise
Authors: Anita Slomski
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CNS Relapse Risk in Consecutive R-CHOP/R-Mini-CHOP-Treated Elderly DLBCL Is Low, with High Risk Particularly Apparent in Those with CNS IPI 5-6 and/or Renal/Adrenal Involvement
Authors: Toby A. Eyre, Nicolas Martinez-Calle, Amy A Kirkwood, Catherine Hildyard, Murali Kesavan, Joseph Butler, Carolyn Mercer, Faouzi Djebbari, Hannah Plaschkes, John Griffith, Stephen Booth, Andrew McMillan, Mark Bishton, Christopher P. Fox, Graham P. Collins, Chris Hatton
Journal: Blood (2018)
Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome
Authors: Giuseppe Gargiulo, Greta Carrara, Enrico Frigoli, Sergio Leonardi, Pascal Vranckx, Gianluca Campo, Ferdinando Varbella, Paolo Calabrò, Tiziana Zaro, Davide Bartolini, Carlo Briguori, Giuseppe Andò, Maurizio Ferrario, Ugo Limbruno, Salvatore Colangelo, Paolo Sganzerla, Filippo Russo, Marco Stefano Nazzaro, Giovanni Esposito, Giuseppe Ferrante, Andrea Santarelli, Gennaro Sardella, Stephan Windecker, Marco Valgimigli
Journal: Journal of the American College of Cardiology (2019)
HBV infection-induced liver cirrhosis development in dual-humanised mice with human bone mesenchymal stem cell transplantation
Authors: Lunzhi Yuan, Jing Jiang, Xuan Liu, Yali Zhang, Liang Zhang, Jiaojiao Xin, Kun Wu, Xiaoling Li, Jiali Cao, Xueran Guo, Dongyan Shi, ­Jun Li­, Longyan Jiang, Suwan Sun, Tengyun Wang, Wangheng Hou, Tianying Zhang, Hua Zhu, Jun Zhang, Quan Yuan, Tong Cheng, Jun Li, Ningshao Xia
Journal: Gut (2019)

Objective Developing a small animal model that accurately delineates the natural history of hepatitis B virus (HBV) infection and immunopathophysiology is necessary to clarify the mechanisms of host-virus interactions and to identify intervention strategies for HBV-related liver diseases. This study aimed to develop an HBV-induced chronic hepatitis and cirrhosis mouse model through transplantation of human bone marrow mesenchymal stem cells (hBMSCs). Design Transplantation of hBMSCs into Fah -/- Rag2 -/- IL-2Rγc -/- SCID (FRGS) mice with fulminant hepatic failure (FHF) induced by hamster-anti-mouse CD95 antibody JO2 generated a liver and immune cell dual-humanised (hBMSC-FRGS) mouse. The generated hBMSC-FRGS mice were subjected to assessments of sustained viremia, specific immune and inflammatory responses and liver pathophysiological injury to characterise the progression of chronic hepatitis and cirrhosis after HBV infection. Results The implantation of hBMSCs rescued FHF mice, as demonstrated by robust proliferation and transdifferentiation of functional human hepatocytes and multiple immune cell lineages, including B cells, T cells, natural killer cells, dendritic cells and macrophages. After HBV infection, the hBMSC-FRGS mice developed sustained viremia and specific immune and inflammatory responses and showed progression to chronic hepatitis and liver cirrhosis at a frequency of 55% after 54 weeks. Conclusion This new humanised mouse model recapitulates the liver cirrhosis induced by human HBV infection, thus providing research opportunities for understanding viral immune pathophysiology and testing antiviral therapies in vivo.